trial

A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder

NCTId NCT00240721
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 363 (actual)
Sponsored by Johnson & Johnson
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
363 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2000-10
Primary completion
—
Eligibility
ALL · 16 Years

Interventions & indications

Drugs
topiramate

Sponsors

Johnson & JohnsonLead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
363
Phase
PHASE3
Status
COMPLETED
relationships
The graph out of here
drug
topiramate
drug
lead_sponsor
Johnson & Johnson
company
indication
Mania
indication
Bipolar Disorder
indication
Bipolar Disorders
indication